J&J(JNJ)
Search documents
Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth
Seeking Alpha· 2024-10-11 21:19
Johnson & Johnson (NYSE: JNJ ) , a global healthcare giant with roots going back to 1886, is set to drop its earnings report for the fiscal quarter ending September 2024. The company, known for its wide range of medical devices, pharmaceuticals, and consumerThe mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap compani ...
What Trends Will Drive Johnson & Johnson's Q3 Results?
Forbes· 2024-10-11 11:00
CHINA - 2023/02/15: In this photo illustration, the American multinational medical devices and ... [+] pharmaceutical company Johnson & Johnson (J&J) logo is seen displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q3 2024 results on Tuesday, October 15. We expect the company to post revenue of $22.2 bi ...
What You Need to Know Ahead of Johnson & Johnson's Earnings
Investopedia· 2024-10-11 09:10
Analyst Estimates for Q3 2024Q2 2024Q3 2023Revenue$22.18 billion$22.45 billion$21.35 billionDiluted EPS$1.80$1.93$1.69Net Income$4.38 billion$4.69 billion$4.31 billion Key Metric: Updated Outlook After V-Wave Adjustment The company has shifted its full-year outlook in each of its first two quarters, and recently said it expects to do so again. In the first quarter, the company narrowed its full-year sales and profit estimates, and in the second quarter lifted its sales estimates while lowering profit pro ...
Johnson & Johnson: You Need To Look At This Chart (Rating Upgrade)
Seeking Alpha· 2024-10-10 15:10
I last wrote on Johnson & Johnson (NYSE: JNJ ) stock back in August 2024. In an article titled "Johnson & Johnson: Don't Bet Against Double Compounding ", I argued for a buy As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despit ...
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
ZACKS· 2024-10-10 14:20
Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2.19 per share in its forthcoming report, representing a decline of 17.7% year over year. Revenues are projected to reach $22.19 billion, increasing 3.9% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during t ...
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
Prnewswire· 2024-10-10 12:00
TREMFYA® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA® VIENNA, Austria, Oct. 10, 2024 /PRNewswire/ -- John ...
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients
GlobeNewswire News Room· 2024-10-10 08:42
Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy1 Data showed that the daratumumab subcutaneous formulation-based quadruplet regimen significantly improved minimal residual disease (MRD)-negativity and reduced the risk of progression or death compared to standard of care regimen1 BEERSE, BELGIUM , Oct. 10, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & J ...
Johnson & Johnson (JNJ) Completes Acquisition of V-Wave Ltd for $600 Million
Gurufocus· 2024-10-09 15:32
Johnson & Johnson (JNJ, Financial) has finalized the acquisition of V-Wave Ltd, a private medical device company. The pharmaceutical giant agreed to purchase V-Wave for an upfront payment of $600 million. This transaction is considered an asset acquisition and will result in approximately $600 million in in-process research and development expenses in the fourth quarter of 2024.V-Wave, which specializes in cardiovascular disease treatment solutions, will now operate as part of Johnson & Johnson's medtech di ...
Should Investors Consider High Yield Dividend Stocks?
ZACKS· 2024-10-09 00:50
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield.But are high-yield stocks always the best route for income-focused investors? Let’s break it down.Are High-Yield Stocks Best?At a quick glance, a dividend-paying stock with an annual yield above 10% indeed seems like a solid investment from an income-focused standpoint. This is particularly true from a shorter-term perspective, but it’s not always that simple and clear-cut.Dividend yields fl ...
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
Benzinga· 2024-10-08 18:00
Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.Following an Independent Data Monitoring Committee recommendation and pre-specified interim analysis, SunRISe-2 was discontinued for not showing superiority versus chemoradiation.“We remain confident in the TARIS platform having over $5 billion potential,” ...